Reliable Brokers
Online Investing
Alerts & Analysis
Easy Trading

Drug administration starts punitive measures against faulty pharmaceuticals companies

Update : 09 May 2014, 09:00 PM

The Directorate General of Drug Administration has started taking punitive actions against the substandard pharmaceutical companies that have been flouting rules and manufacturing drugs.

As part of its latest move, the administration cancelled the drug licence of Mystic Pharmaceuticals Ltd, as well as prohibiting it from the manufacture, sales and marketing of drugs.

Brig Gen Md Zahangir Hossain Mollick, director general of the Directorate General of Drug Administration (DGDA), said: “We will show zero tolerance toward pharmaceutical companies manufacturing substandard drugs.”

Mystic Pharmaceuticals is one of the 62 companies which had been detected as substandard company by the parliamentary committee of Health Ministry. They have been found guilty of malpractice as they have been manufacturing drugs in violation of the World Health Organization and Good Manufacturing Practice guidelines for years. 

A high official of the DGDA told the Dhaka Tribune the authorities will cancel the drug licence of a couple of companies very soon. 

The DGDA issued show cause notices to 15 pharmaceutical companies which were previously identified as the manufacturers of substandard drugs, asking them to explain within 15 days why their licences should not be cancelled.

The drug administration made the move following the directives from the Health Ministry on April 20.

The DGDA served a show cause notice to Mystic Pharmaceuticals Ltd based in Narsingdi on February 18 after its inquiry into the drug company. 

The inquiry report mentioned that Mystic Pharmaceuticals Ltd was not following the GMP guidelines.

The Dhaka Tribune obtained a copy of the suspension order in which the DGDA mentioned 12 valid reasons for cancelling the drug company’s licence.

The investigation team found a shortage of manpower and no microbiologists in the drug industry.

A plant in-charge was the only official who looked after manufacture and quality control.

There was even no quarantine area or finished product store for the manufactured drugs.

The manufacture of substandard drugs came into the spotlight in 2010 following the deaths of 24 children who took a paracetamol syrup manufactured by Rid Pharmaceuticals Ltd.

The parliamentary body of the Health Ministry formed a probe team that identified 62 companies as producers of fake medicine in 2010.

Later it revised the number of companies and placed it at 73, following a second round of inspections in 2013.

Of the 73, the team found 29 companies posing high risks to public health.

The report mentioned that the 29 did not comply with the World Health Organisation guidelines in manufacturing drugs. 

Top Brokers